May Guo About mRNA Based in Vivo MG1113 Antibody Production as a Potential Therapeutic Approach for Hemophilia
May Guo, Vice President of Business Development at Biomay AG and Founder and CEO of Novaribo Consulting, shared a post on her LinkedIn account:
“mRNA/LNP encoding MG1113, a humanized monoclonal antibody that targets tissue factor pathway inhibitor (TFPI), to treat hemophilia. This paper shows that a single IV dose of mRNA-LNP achieves substantially higher peak serum concentrations of MG1113 antibody compared with direct antibody administration, demonstrating the pharmacokinetic advantage of mRNA-encoded antibody delivery.”
Title: mRNA based in vivo MG1113 antibody production as a potential therapeutic approach for hemophilia
Authors: Miyoung Oh, Yujeong Jeong, Hyein Jung, Yongjoo Byeon, Heechun Kwak, Songseop Kim, Wonhyo Seo, Jaesung Jung, Hyukjin Lee
Find more posts on Hemostasis Today.
-
Sep 24, 2026, 16:02Leonardo Roever: Understanding Peripheral Artery Disease in the Modern Era
-
Sep 24, 2026, 15:49Sthanu Subramanian: When HbA1c Does Not Reflect True Glycemia
-
Sep 24, 2026, 15:09Caroline Voltz-Girolt: Accelerating the Development of Innovative Therapies for Rare Blood Disorders
-
Sep 24, 2026, 15:00Gambo Ramatu: Anemia as a Preventable Pregnancy Challenge
-
Sep 24, 2026, 14:56Holly John: Sickle Cell Disease Beyond Pain and Clinical Outcomes
-
Sep 24, 2026, 14:45Bruce Holland: Ex Vivo Assessment of ActiGraft Clot Formation Under Anticoagulation
-
Sep 24, 2026, 14:33Mohamed El Belghiti Alaoui: Thrombin as a Therapeutic Target in Coagulation
-
Sep 24, 2026, 14:22Integrating Thrombosis Risk Into Menopause Care – World Thrombosis Day
-
Sep 24, 2026, 13:41Mahmoud Samir Bayomi: Raise ITP Awareness and Improve Patient Care